168473-49-2

Basic information

• Product Name: 2-<2-bromo-5-(valerylamino)phenyl>-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one
• Synonyms: 2-<2-bromo-5-(valerylamino)phenyl>-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one
• CAS NO: 168473-49-2
• Molecular Weight: 686.645
• Mol File: 168473-49-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-<2-bromo-5-(valerylamino)phenyl>-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-<2-bromo-5-(valerylamino)phenyl>-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one(168473-49-2)
• EPA Substance Registry System: 2-<2-bromo-5-(valerylamino)phenyl>-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one(168473-49-2)

Safety Data

• Hazardous Substances Data: 168473-49-2(Hazardous Substances Data)

Upstream product

• 168473-47-0 2-(2-bromo-5-nitrophenyl)-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one 
• 159547-21-4 [3-Fluoro-2'-(N-t-butylsulfamoyl)biphenyl-4-yl]methyl Bromide 
• 159547-20-3 3-Fluoro-4-methyl-2'-(N-t-butylsulfamoyl)biphenyl 
• 150691-04-6 2-(tert-butylamino)sulfonylphenylboronic acid 
• 51436-99-8 2-fluoro-4-bromotoluene 
• 638-29-9 n-valeryl chloride 
• 168473-48-1 2-(5-amino-2-bromophenyl)-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-5-ethyl-3H-1,2,4-triazol-3-one 

Downstream Products

• 168473-50-5 2-[2-Bromo-5-(valerylamino)phenyl]-2,4-dihydro-5-ethyl-4-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)methyl]-3H-1,2,4-triazol-3-one 

Relevant articles and documents

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes

In order to block the effects induced by the interactions between angiotensin II (AII) and both AT1 and AT2 receptors, we have pursued the discovery of orally active non-peptide AII antagonists that exhibit potent and equal affinity